Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Co-careldopa M/R tablets
Co-careldopa tablets
Colestipol		RICaD in development
Colestyramine sachets
Colestyramine sachets		Jaundice and PBC
Colistimethate sodium	TA276 - Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis	Amber: Existing patients (initiated prior to April 2013) Promixin® - Powder for nebuliser solution Colomycin® Injection may be used for nebulisation; administer required dose in 2-4 mL of sodium chloride 0.9%, (or water for injections) or a 1:1 mixture of sodium chloride 0.9% and water for injection Colobreathe® - Dry powder for inhalation, hard capsule (NICE TA276)
Colomycin nebulised		NHS England Commissioned for Cystic Fibrosis only. Existing patients - initiated prior to April 2013
Combigan eye drops		Specialist ophthalmologist recommendation
Cosopt eye drops		Specialist ophthalmologist recommendation
Cosopt eye drops (preserv free)		Specialist ophthalmologist recommendation

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.